Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer

Giorgio Bolis, Fabio Parazzini, Giovanna Scarfone, Antonella Villa, Mariangela Amoroso, Emanuela Rabaiotti, Anna Polatti, Simona Reina, Elena Pirletti

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'Paclitaxel vs epidoxorubicin plus paclitaxel as second-line therapy for platinum-refractory and -resistant ovarian cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences